Literature DB >> 21610203

Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers.

M R Lofwall1, D E Moody, W B Fang, P A Nuzzo, S L Walsh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21610203      PMCID： PMC4006196          DOI： 10.1177/0091270011401620

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  26 in total

Review 1.  College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement.

Authors:  James Zacny; George Bigelow; Peggy Compton; Kathleen Foley; Martin Iguchi; Christine Sannerud
Journal:  Drug Alcohol Depend       Date:  2003-04-01       Impact factor: 4.492

2.  Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution.

Authors:  D P Benziger; R F Kaiko; J B Miotto; R D Fitzmartin; R F Reder; M Chasin
Journal:  J Pharm Sci       Date:  1996-04       Impact factor: 3.534

3.  The pharmacokinetics of oxycodone after intravenous injection in adults.

Authors:  R Pöyhiä; K T Olkkola; T Seppälä; E Kalso
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

4.  Bioavailability of apomorphine following intranasal administration of mucoadhesive drug delivery systems in rabbits.

Authors:  M I Ugwoke; S Exaud; G Van Den Mooter; N Verbeke; R Kinget
Journal:  Eur J Pharm Sci       Date:  1999-12       Impact factor: 4.384

5.  Self-induced pulmonary granulomatosis. A consequence of intravenous injection of drugs intended for oral use.

Authors:  B F Waller; W J Brownlee; W C Roberts
Journal:  Chest       Date:  1980-07       Impact factor: 9.410

6.  Nasal insulin delivery with dimethyl-beta-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations.

Authors:  N G Schipper; S G Romeijn; J C Verhoef; F W Merkus
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

7.  Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone.

Authors:  A Takala; V Kaasalainen; T Seppälä; E Kalso; K T Olkkola
Journal:  Acta Anaesthesiol Scand       Date:  1997-02       Impact factor: 2.105

8.  The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects.

Authors:  R Pöyhiä; T Seppälä; K T Olkkola; E Kalso
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

9.  Overdose deaths involving prescription opioids among Medicaid enrollees - Washington, 2004-2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-10-30       Impact factor: 17.586

10.  Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer.

Authors:  W T Beaver; S L Wallenstein; R W Houde; A Rogers
Journal:  J Clin Pharmacol       Date:  1977-04       Impact factor: 3.126
View more
  14 in total

Review 1.  Intranasal therapy with opioids for children and adolescents with cancer: results from clinical studies.

Authors:  Silvia Triarico; Michele Antonio Capozza; Stefano Mastrangelo; Giorgio Attinà; Palma Maurizi; Antonio Ruggiero
Journal:  Support Care Cancer       Date:  2019-06-01       Impact factor: 3.603

2.  Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers.

Authors:  Sharon L Walsh; Markus Heilig; Paul A Nuzzo; Pam Henderson; Michelle R Lofwall
Journal:  Addict Biol       Date:  2012-01-19       Impact factor: 4.280

3.  Effects of cold pressor pain on the abuse liability of intranasal oxycodone in male and female prescription opioid abusers.

Authors:  Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2011-12-30       Impact factor: 4.492

Review 4.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

5.  Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.

Authors:  Wenfang B Fang; Michelle R Lofwall; Sharon L Walsh; David E Moody
Journal:  J Anal Toxicol       Date:  2013-06-05       Impact factor: 3.367

6.  Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens.

Authors:  Marco Pravetoni; Morgan Le Naour; Ashli M Tucker; Theresa M Harmon; Tara M Hawley; Philip S Portoghese; Paul R Pentel
Journal:  J Med Chem       Date:  2013-01-15       Impact factor: 7.446

7.  Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial.

Authors:  Michelle R Lofwall; Shanna Babalonis; Paul A Nuzzo; Anthony Siegel; Charles Campbell; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2013-06-04       Impact factor: 4.492

Review 8.  The effects of opioids on the lung.

Authors:  Joshua B Radke; Kelly P Owen; Mark E Sutter; Jonathan B Ford; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2014-02       Impact factor: 8.667

9.  Opposing mechanisms underlying differential changes in brain oxygen and temperature induced by intravenous morphine.

Authors:  Ernesto Solis; Anum Afzal; Eugene A Kiyatkin
Journal:  J Neurophysiol       Date:  2018-09-05       Impact factor: 2.714

10.  Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults.

Authors:  Peter J Perrino; Salvatore V Colucci; Glen Apseloff; Stephen C Harris
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.